Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...

It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...

This approval is the fifth overall for bimekizumab (Bimzelyx; UCB Pharma) in the US, and they all have come in the last 13 ...

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...

Problems with cognition, memory, and emotional regulation may persist for 3 years or more after a diagnosis of anti-NMDAR ...

FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement.

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...

Chinese pharmaceutical supply chain Darentang Jingwanhong Pharmaceutical ... The WHO added LC16M8 mpox vaccine to its ...

Having absorbed other study stumbles in the past few months, the company now has halted development of dalzanemdor in treating Huntington’s disease after top-line phase II data showed it missed a ...

Major indexes of the stock markets in Bangladesh rose marginally yesterday, snapping a three-day losing streak, as investors ...